Share this Story
(Bloomberg) — Moderna Inc. shares slid 3.5% on Friday as unease mounted about the biotech’s Covid-19 vaccine trial fueled by ongoing insider shares sales and an enrollment slowdown.With late-stage trial results weeks away, the stock has shed more than a thir…